Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Foley

Showing results (121-130 of 185) with videos related to

Pageof 19
Sort By:
Plos One|March 29, 2024
Brain connectivity changes underlying depression and fatigue in relapsing-remitting multiple sclerosis: A systematic reviewAgniete Kampaite, Rebecka Gustafsson, Elizabeth N York, et al.
Journal of the American Academy of Dermatology|March 15, 2017
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III studyKim Papp, Herve Bachelez, Antonio Costanzo, et al.
The Australasian Journal of Dermatology|May 26, 2017
Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis CollaborationMarius Rademaker, Karen Agnew, Megan Andrews, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialKenneth B Gordon, Peter Foley, James G Krueger, et al.
The Australasian Journal of Dermatology|September 19, 2019
Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrativeMarius Rademaker, Karen Agnew, Megan Andrews, et al.
The Journal of Sexual Medicine|November 13, 2018
Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind StudyGil Yosipovitch, Peter Foley, Caitriona Ryan, et al.
Journal of Drugs in Dermatology : JDD|February 6, 2025
Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc AnalysesKenneth B Gordon, Joseph F Merola, Peter Foley, et al.
International Journal of Rheumatic Diseases|May 23, 2019
Initial assessment of the early arthritis for psoriatic patients diagnostic questionnaire in dermatology clinics in Australia, Korea and ChinaSeong-Jin Jo, Peter Foley, Stephen Philip Oakley, et al.
The Journal of Investigative Dermatology|May 25, 2012
Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trialKim A Papp, Cathy Reid, Peter Foley, et al.
The Australasian Journal of Dermatology|April 2, 2015
Treatment of face and scalp solar (actinic) keratosis with daylight-mediated photodynamic therapy is possible throughout the year in Australia: Evidence from a clinical and meteorological studyLynda Spelman, Diana Rubel, Dedee F Murrell, et al.
Pageof 19

Showing results (121-130 of 185) with videos related to

Sort By:
Pageof 19
Plos One|March 29, 2024
Brain connectivity changes underlying depression and fatigue in relapsing-remitting multiple sclerosis: A systematic reviewAgniete Kampaite, Rebecka Gustafsson, Elizabeth N York, et al.
Journal of the American Academy of Dermatology|March 15, 2017
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III studyKim Papp, Herve Bachelez, Antonio Costanzo, et al.
The Australasian Journal of Dermatology|May 26, 2017
Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis CollaborationMarius Rademaker, Karen Agnew, Megan Andrews, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialKenneth B Gordon, Peter Foley, James G Krueger, et al.
The Australasian Journal of Dermatology|September 19, 2019
Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrativeMarius Rademaker, Karen Agnew, Megan Andrews, et al.
The Journal of Sexual Medicine|November 13, 2018
Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind StudyGil Yosipovitch, Peter Foley, Caitriona Ryan, et al.
Journal of Drugs in Dermatology : JDD|February 6, 2025
Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc AnalysesKenneth B Gordon, Joseph F Merola, Peter Foley, et al.
International Journal of Rheumatic Diseases|May 23, 2019
Initial assessment of the early arthritis for psoriatic patients diagnostic questionnaire in dermatology clinics in Australia, Korea and ChinaSeong-Jin Jo, Peter Foley, Stephen Philip Oakley, et al.
The Journal of Investigative Dermatology|May 25, 2012
Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trialKim A Papp, Cathy Reid, Peter Foley, et al.
The Australasian Journal of Dermatology|April 2, 2015
Treatment of face and scalp solar (actinic) keratosis with daylight-mediated photodynamic therapy is possible throughout the year in Australia: Evidence from a clinical and meteorological studyLynda Spelman, Diana Rubel, Dedee F Murrell, et al.
Pageof 19